Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Passage BIO, Inc.PASG · Entity 7829 | Chief Technical Officer | June 15, 2023 | June 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Passage BIO, Inc.
Report date June 15, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,693 |
Ending reported balance
After 2023-06-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-15 · Exercise / conversion · Acquired 12,500 · Balance 32,745 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Row 2 · 2023-06-16 · Sale · Disposed 4,052 · Balance 28,693 F2: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,000 |
Reported balance
After 2023-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-15 · Exercise / conversion · Disposed 12,500 · Balance 25,000 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3: 1/4 of the RSUs vested on June 15, 2022, and the remainder vested or vests as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3: 1/4 of the RSUs vested on June 15, 2022, and the remainder vested or vests as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2023 Filed Jun 20, 2023 20:10 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 4,052 | $0.93 | $3,778.49 |
DisclosureSEC source: 0001209191-23-038345 · doc4.xml · nonDerivative · entry 2 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,693 F2 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:10 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038345 · doc4.xml · derivative · entry 3 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 1/4 of the RSUs vested on June 15, 2022, and the remainder vested or vests as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:10 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038345 · doc4.xml · nonDerivative · entry 1 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| March 15, 2023 Filed Apr 5, 2023 23:27 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-23-023476 · doc4.xml · derivative · entry 1 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The stock option vests as of 1/48 of the total shares monthly beginning on April 15, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 21:15 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058795 · doc4.xml · derivative · entry 3 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F4 · kind: The reported transaction represents the settlement of restricted stock units which vested on June 15, 2022 but for which settlement was delayed due to an inadvertent administrative error. F5 · derivative.exercise_date: 1/4 of the RSUs vested on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F6 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 21:15 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 3,720 | $1.33 | $4,947.60 |
DisclosureSEC source: 0001209191-22-058795 · doc4.xml · nonDerivative · entry 2 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,245 F3 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. F2 · balance_after: The reported total includes 3,082 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 21:15 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058795 · doc4.xml · nonDerivative · entry 1 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · balance_after: The reported total includes 3,082 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:21 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056609 · doc4.xml · derivative · entry 1 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 100% of the total RSUs will vest on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: 100% of the total RSUs will vest on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 21:21 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001209191-22-037050 · doc4.xml · derivative · entry 1 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on July 13, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:14 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantStock Option (right to buy) · Derivative | 163,900 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001787297-22-000004 · primary_doc.xml · derivative · entry 2 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,900 Underlying: Common Stock · 163,900 shares Expires 2032-02-09 F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 23:04 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Unit (RSU) · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034185 · doc4.xml · derivative · entry 1 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 1/4 of the RSUs will vest on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 1/4 of the RSUs will vest on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:24 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $21.85 | $0.00 |
DisclosureSEC source: 0001209191-21-012154 · doc4.xml · derivative · entry 2 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2031-02-15 F2 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 03, 2020 Filed Mar 3, 2020 23:38 UTC | Passage BIO, Inc. PASG · Entity 7829 | PurchaseCommon Stock | 5,500 | $18.00 | $99,000.00 |
DisclosureSEC source: 0001209191-20-015621 · doc4.xml · nonDerivative · entry 1 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:50 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (Right to Buy) · Derivative | 74,311 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014691 · doc4.xml · derivative · entry 1 Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,311 Underlying: Common Stock · 74,311 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on February 27, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 27, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.